ClinicalTrials.gg
CompletedNCT03688802Updated Dec 29, 2021Results posted

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

A Phase 2 interventional study of OC-01 (varenicline) nasal spray and Placebo (vehicle control) nasal spray in Dry Eye Disease, sponsored by Oyster Point Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.

Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.

Enrollment
12th of 13
18 · median 60
Started
2018
with 1 other
Phase 2
3 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
Oyster Point Pharma, Inc.

Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing varenicline in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.

Read the detailed description

This was a Phase 2, single-center, randomized, masked (including all subjects, investigators, and study site personnel), placebo-controlled study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in stimulating goblet cell and Meibomian gland function in in adult subjects with DED. Approximately 45 subjects at least 18 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria were planned to be randomized to receive a single application of 0.2% (1.2 mg/mL) OC-01 or placebo

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to visit 1.

Exclusion criteria

Exclusion Criteria:

  • Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such as blepharoplasty) in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1
  • Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Have a known to any of the procedural agents or study drug components
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    OC-01 (varenicline) nasal spray, 1.2 mg/mL

    OC-01 (varenicline) nasal spray, 1.2 mg/mL, one time dosing

    Drug: OC-01 (varenicline) nasal spray

  • Placebo comparator
    Placebo (vehicle control) nasal spray

    Placebo (vehicle control) nasal spray, one time dosing

    Drug: Placebo (vehicle control) nasal spray

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Goblet Cell Area

    Mean change in Goblet Cell Area with a larger decrease is indicative of a better outcome.

    Time frame: Baseline (pre-treatment), 1 day (post treatment)

  2. Mean Change in Goblet Cell Perimeter

    Mean change in Goblet Cell Perimeter. A larger decrease is indicative of a better outcome.

    Time frame: Baseline (pre-treatment), 1 day (post treatment)

  3. Change in Meibomian Gland Area, Upper Lid

    Change in Meibomian gland area, upper lid. A larger decrease is indicative of a better outcome

    Time frame: Baseline (pre-treatment), 1 day (post treatment)

  4. Mean Change in Meibomian Gland Area, Lower Lid.

    Mean change in Meibomian Gland Area, lower Lid. A larger decrease is indicative of a better outcome.

    Time frame: Baseline (pre-treatment), 1 day (post treatment)

  5. Mean Change in Meibomian Gland Perimeter, Upper Lid.

    Chane in Meibomian Gland Perimeter, upper lid. A larger decrease is indicative of a better outcome.

    Time frame: Baseline (pre-treatment), 1 day (post treatment)

  6. Mean Change in Meibomian Gland Perimeter, Lower Lid

    Mean change in Meibomian Gland Perimeter, lower lid. A larger decrease is indicative of a better outcome.

    Time frame: Baseline (pre-treatment), 1 day (post treatment)

07

Results

Posted Dec 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneOC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal Spray
Started126
Completed116
Not completed10

Outcome measures

PrimaryMean Change in Goblet Cell Area

Mean change in Goblet Cell Area with a larger decrease is indicative of a better outcome.

Time frame:
Baseline (pre-treatment), 1 day (post treatment)
Reported as:
Mean · um
Mean Change in Goblet Cell Area
umOC-01, 1.2 mg/mLPlacebo
Mean Change in Goblet Cell Area-38.8 ± 30.20-6.7 ± 1.94
PrimaryMean Change in Goblet Cell Perimeter

Mean change in Goblet Cell Perimeter. A larger decrease is indicative of a better outcome.

Time frame:
Baseline (pre-treatment), 1 day (post treatment)
Reported as:
Mean · um
Mean Change in Goblet Cell Perimeter
umOC-01, 1.2 mg/mLPlacebo
Mean Change in Goblet Cell Perimeter-7.7 ± 5.79-1.8 ± 0.76
PrimaryChange in Meibomian Gland Area, Upper Lid

Change in Meibomian gland area, upper lid. A larger decrease is indicative of a better outcome

Time frame:
Baseline (pre-treatment), 1 day (post treatment)
Reported as:
Mean · um
Change in Meibomian Gland Area, Upper Lid
umOC-01, 1.2 mg/mLPlacebo
Change in Meibomian Gland Area, Upper Lid11.2 ± 118.6-143.2 ± 154.8
PrimaryMean Change in Meibomian Gland Area, Lower Lid.

Mean change in Meibomian Gland Area, lower Lid. A larger decrease is indicative of a better outcome.

Time frame:
Baseline (pre-treatment), 1 day (post treatment)
Reported as:
Mean · um
Mean Change in Meibomian Gland Area, Lower Lid.
umOC-01, 1.2 mg/mLPlacebo
Mean Change in Meibomian Gland Area, Lower Lid.-29.9 ± 88.1-12.4 ± 95.8
PrimaryMean Change in Meibomian Gland Perimeter, Upper Lid.

Chane in Meibomian Gland Perimeter, upper lid. A larger decrease is indicative of a better outcome.

Time frame:
Baseline (pre-treatment), 1 day (post treatment)
Reported as:
Mean · um
Mean Change in Meibomian Gland Perimeter, Upper Lid.
umOC-01, 1.2 mg/mLPlacebo
Mean Change in Meibomian Gland Perimeter, Upper Lid.6.15 ± 16.6-19.2 ± 22.8
PrimaryMean Change in Meibomian Gland Perimeter, Lower Lid

Mean change in Meibomian Gland Perimeter, lower lid. A larger decrease is indicative of a better outcome.

Time frame:
Baseline (pre-treatment), 1 day (post treatment)
Reported as:
Mean · um
Mean Change in Meibomian Gland Perimeter, Lower Lid
umOC-01, 1.2 mg/mLPlacebo
Mean Change in Meibomian Gland Perimeter, Lower Lid-4 ± 10.94.2 ± 19.3

Adverse events

Collected over Adverse events were collected from the time of study drug administration to the last study visit (pre to post treatment 1 day).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OC-01, 1.2 mg/mL0/12 (0%)0/12 (0%)6/12 (50%)
Placebo0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventOC-01, 1.2 mg/mLPlacebo
SneezingRespiratory, thoracic and mediastinal disorders5/121/6
Nasal discomfortRespiratory, thoracic and mediastinal disorders2/120/6
TEAEEye disorders0/120/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)OC-01, 1.2 mg/mLPlaceboTotal
Mean60.5 ± 13.7963.3 ± 13.4661.4 ± 13.35
Sex: Female, Male
Sex: Female, Male(Participants)OC-01, 1.2 mg/mLPlaceboTotal
Female11314
Male134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OC-01, 1.2 mg/mLPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino11617
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OC-01, 1.2 mg/mLPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American202
White9615
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)OC-01, 1.2 mg/mLPlaceboTotal
United States12618
Schirmer's Test Score
Schirmer's Test Score(mm)OC-01, 1.2 mg/mLPlaceboTotal
Mean6.6 ± 4.424.5 ± 3.895.9 ± 4.25
08

Study locations

1 site
  • Tufts
    Boston, Massachusetts 02111, United States
09

References and documents

Publications

  • Dieckmann GM, Cox SM, Lopez MJ, Ozmen MC, Yavuz Saricay L, Bayrakutar BN, Binotti WW, Henry E, Nau J, Hamrah P. A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease. Ophthalmol Ther. 2022 Aug;11(4):1551-1561. doi: 10.1007/s40123-022-00530-x. Epub 2022 Jun 2. PubMed 35653029 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Sep 2019, 12 months.

Results were first posted in Dec 2021, 2 years 2 months after primary completion. A results delay was requested in Jan 2021.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 12 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Sep 28, 2018
StartActual
Sep 25, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Results delay requested
Jan 26, 2021
Results first posted
Dec 29, 2021
Last update
Dec 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03688802
Responsible party
Sponsor
First posted
Sep 28, 2018
Start date
Sep 25, 2018
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Results posted
Dec 29, 2021
Last update
Dec 29, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion